tocilizumab + obinutuzumab + chlorambucil

This is a **three-drug combination therapy** consisting of **tocilizumab**, **obinutuzumab**, and **chlorambucil**. - **Obinutuzumab** is a type II anti-CD20 monoclonal antibody designed to induce direct cell death and promote antibody-dependent cell-mediated cytotoxicity against B cells. It is approved, in combination with chlorambucil, for first-line treatment of chronic lymphocytic leukemia (CLL)[3][6][1][2]. - **Chlorambucil** is an oral alkylating agent from the nitrogen mustard class, used as a chemotherapy drug, especially in CLL. It binds to DNA and inhibits replication and transcription, leading to cell death. - **Tocilizumab** is a monoclonal antibody that blocks the interleukin-6 (IL-6) receptor, approved for indications involving cytokine release syndrome and used experimentally or off-label to mitigate infusion-related cytokine release syndromes and inflammatory events associated with antibody-based therapies such as obinutuzumab[5][4]. This three-drug regimen is being investigated in clinical contexts where tocilizumab is given prophylactically or as a treatment to reduce infusion-related reactions and cytokine release associated with obinutuzumab administration in CLL therapy[4][5].